FK1706

06/01/2012 - "FK1706 ameliorates mechanical allodynia with accompanying increases in gene expressions possibly related to neurite outgrowth, development, differentiation, and nociceptive sensitivity."
06/01/2012 - "Here, we analyzed gene expression of the dorsal root ganglia using microarray together with behavioral measurement of mechanical allodynia in diabetic rats to try to capture the global fingerprint of changes in gene expression associated with FK1706 administration. "
06/01/2012 - "The gene expression of the ganglia from L4 to L6 obtained from streptozotocin-treated rats with or without chronic administration of FK1706 was analyzed using an Affymetrix GeneChip to extract interesting genes in the development of mechanical allodynia in diabetes and anti-allodynia effect of FK1706. "
12/01/2008 - "FK1706 ameliorated mechanical allodynia in this model at doses over 0.32 mg/kg, p.o., even if treatment was initiated after neuropathy was established, and did not affect plasma glucose levels. "
06/01/2012 - "Daily oral administration of FK1706 improved mechanical allodynia without decreasing plasma glucose levels. "

12/01/2008 - "Thus, FK1706 ameliorated painful diabetic neuropathy via a different mechanism from gabapentin and improved morphological outcomes, indicating that FK1706 improves painful diabetic neuropathy by modifying the underlying disease pathology."
12/01/2008 - "Here, we tested the effect of FK1706 on painful diabetic neuropathy in rat model of diabetes induced by streptozotocin (STZ). "
06/01/2012 - "FK1706, a novel non-immunosuppressive immunophilin ligand, modifies gene expression in the dorsal root ganglia during painful diabetic neuropathy."
12/01/2008 - "FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy."

09/04/2008 - "Taken together, FK1706 improves both behavioral motor function and the underlying morphological changes, suggesting that FK1706 may have therapeutic potential in meeting the significant unmet needs in spinal cord injury."
09/04/2008 - "FK1706, a novel non-immunosuppressant neurophilin ligand, ameliorates motor dysfunction following spinal cord injury through its neuroregenerative action."
09/04/2008 - "FK1706, a non-immunosuppressant neurophilin ligand, potentiates nerve growth factor signaling, suggesting therapeutic potential for functional deficits following spinal cord injury. "

02/07/2022 - "FK1706 warrants in vivo testing as a potential new combination therapeutic for the treatment of COVID-19 infections."

02/07/2022 - "FK1706 warrants in vivo testing as a potential new combination therapeutic for the treatment of COVID-19 infections."